FGFR4 and hepatocellular carcinoma: As lenvatinib has a strong inhibitory effect of FGFR4 signaling pathway with IC50 to FGFR4 of 43 nM/L, [47] higher response rate (81% vs. 31%) and better PFS (5.5 M vs. 2.5 M) were observed in HCC patients with high FGFR4 expression (positive β-catenin activation) than those with low FGFR4 expression [48].